Leading R&D Innovations | Takeda Oncology

At Takeda Oncology, we are growing our pipeline through a combination of internal innovation and strategic collaboration. Our research and development efforts focus on advancing medicines for thoracic, gastrointestinal and hematologic cancers, using modalities best suited to make a meaningful difference in these areas.

Our core modalities include antibody-drug conjugates (ADCs), complex biologics, small molecules, and gamma delta T cell therapies. With extensive experience in small molecule development, including proteasome inhibitors for hematologic cancers, and a strong foundation in ADC manufacturing and early-stage programs, we are well-positioned to advance these innovative therapies.

By working with partners whose investigational therapies complement our research expertise and global commercial capabilities, we aim to expand our impact and accelerate promising treatments.